In short
BMS-986365 (also known as CC-94676) is an investigational drug currently being studied in various clinical trials to evaluate its safety, efficacy, and pharmacological properties. The clinical trials range from early Phase 1 studies in healthy volunteers to advanced Phase 3 trials in patients with metastatic castration-resistant prostate cancer (mCRPC). These studies aim to understand how the drug works in the body, how it's processed, and most importantly, how it compares to existing treatments for prostate cancer. The research is designed to provide crucial information about proper dosing, potential side effects, and the overall benefit-risk profile of BMS-986365 before it can be considered for wider use in patient care.
Key points
- BMS-986365 (also known as CC-94676) is an investigational drug currently being evaluated in clinical trials for metastatic castration-resistant prostate cancer and undergoing testing in healthy volunteers. Early phase studies are examining how the drug behaves in the body, including its absorption, distribution, metabolism, and elimination patterns, as well as the effects of food and acid-reducing medications on its performance. A large Phase 3 trial called "rechARge" is comparing BMS-986365 against standard prostate cancer treatments like docetaxel and androgen receptor pathway inhibitors to determine if it provides better outcomes for patients. The research aims to determine the optimal dosing, potential side effects, and whether BMS-986365 can improve survival and quality of life compared to existing therapies for advanced prostate cancer.
What is BMS-986365?
BMS-986365 (also known as CC-94676) is an investigational medication currently being studied in clinical trials. It is not yet approved by regulatory agencies for widespread use and is still in the research and development phase. The drug is being developed by Bristol Myers Squibb, as indicated by the "BMS" prefix in its name.
At this stage, researchers are conducting various studies to understand how the drug works in the body, including how it's absorbed, distributed, metabolized, and eliminated. These studies are essential steps in determining whether BMS-986365 could be safe and effective for treating specific conditions.
What Conditions Does BMS-986365 Treat?
Based on the clinical trial information available, BMS-986365 is primarily being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This is an advanced form of prostate cancer that has spread beyond the prostate to other parts of the body (metastasized) and continues to progress despite treatments that lower testosterone levels (castration therapy).
Metastatic castration-resistant prostate cancer represents one of the most challenging stages of prostate cancer to treat, as the cancer has developed resistance to standard hormone therapy approaches. New treatment options are needed for patients at this stage, which is why drugs like BMS-986365 are being investigated.
Current Clinical Research
BMS-986365 is currently being studied in several clinical trials that are designed to evaluate different aspects of the drug's properties and effectiveness:
Phase 1 Studies
Two Phase 1 studies are focusing on understanding how BMS-986365 works in the body of healthy volunteers:
- A study evaluating the safety, tolerability, and pharmacokinetics (how the drug moves through the body) of BMS-986365 at different doses. This study also examines how food and acid-reducing medications like rabeprazole (a proton pump inhibitor) might affect how the drug is absorbed.
- A study looking at how BMS-986365 is metabolized and excreted from the body, as well as its absolute bioavailability (the percentage of the drug that enters circulation when introduced into the body). This research uses radioactively labeled versions of the drug ([14C] BMS-986365) to track its movement through the body.
Phase 3 Study
A more advanced Phase 3 clinical trial called "rechARge" is comparing BMS-986365 to current standard treatments for metastatic castration-resistant prostate cancer. This study is designed to determine if BMS-986365 is more effective than existing therapies.
In this trial, BMS-986365 is being compared to the investigator's choice of:
- Docetaxel plus Prednisone/Prednisolone (a chemotherapy approach), or
- Second Androgen Receptor Pathway Inhibitors (ARPIs) such as:
- Abiraterone plus Prednisone/Prednisolone, or
- Enzalutamide
The primary goal of this Phase 3 trial is to measure radiographic progression-free survival (rPFS), which is the length of time during and after treatment that the cancer does not grow or spread, as determined by imaging tests reviewed by independent experts.
Safety Monitoring and Side Effects
As with all investigational drugs, researchers are carefully monitoring the safety of BMS-986365. The clinical trials are tracking several safety measures, including:
- Adverse events (side effects)
- Serious adverse events
- Changes in laboratory tests (blood tests)
- Electrocardiogram (ECG) findings to monitor heart function
- Vital signs
- Physical examination findings
Since BMS-986365 is still in clinical trials, a complete profile of potential side effects is not yet established. The ongoing studies will help identify what side effects might occur and how common they are.
Drug Interactions and Food Effects
Part of the research on BMS-986365 is examining how other factors might affect how the drug works in the body:
- Food effects: Researchers are studying whether taking BMS-986365 with food (fed state) versus without food (fasted state) affects how well the drug is absorbed.
- Acid-reducing medications: One study is specifically looking at how rabeprazole, a proton pump inhibitor that reduces stomach acid production, might interact with BMS-986365. This is important because many patients with cancer take medications to reduce stomach acid to manage symptoms or side effects of treatment.
Understanding these interactions will help determine the best way to administer BMS-986365 if it eventually receives approval for clinical use.
How BMS-986365 is Administered
The clinical trials indicate that BMS-986365 is being tested in different formulations, including tablets and capsules. Part of the research is comparing how these different formulations are absorbed and utilized by the body (bioavailability).
The exact dosing schedule is still being determined through the clinical trials, with different dose levels being tested to find the optimal balance between effectiveness and safety. In the Phase 3 trial, two different dose levels of BMS-986365 are initially being evaluated in Part 1, with the more promising dose selected for further testing in Part 2.
Comparison to Other Treatments
The Phase 3 clinical trial is directly comparing BMS-986365 to current standard treatments for metastatic castration-resistant prostate cancer. These standard treatments include:
- Docetaxel with Prednisone/Prednisolone: Docetaxel is a chemotherapy drug that works by interfering with cell division, while prednisone helps reduce inflammation and some cancer-related symptoms.
- Androgen Receptor Pathway Inhibitors (ARPIs):
- Enzalutamide: This medication blocks the effect of testosterone and other male hormones on prostate cancer cells.
- Abiraterone with Prednisone/Prednisolone: Abiraterone works by reducing androgen production throughout the body, not just in the testicles.
The clinical trial is measuring not only how BMS-986365 affects cancer progression compared to these treatments but also how it impacts patients' quality of life and pain levels. This is being assessed using standardized questionnaires such as the Functional Assessment of Cancer Therapy - Prostate Cancer (FACT-P) and the Brief Pain Inventory - Short Form (BPI-SF).
If BMS-986365 proves to be more effective than current treatments with a manageable safety profile, it could potentially become an important new option for patients with metastatic castration-resistant prostate cancer.